

Commentary

Open Access



The role of cancer cell-released extracellular vesicles: have we become closer to cancer pain treatment?

Iryna A. Khasabova, Sergey G. Khasabov, Donald A. Simone

Department of Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN 55455, USA.

Correspondence to: Dr. Donald A. Simone, Department of Diagnostic and Biological Sciences, University of Minnesota, 515 Delaware St. SE, Minneapolis, MN 55455, USA. E-mail: simon003@umn.edu

How to cite this article: Khasabova IA, Khasabov SG, Simone DA. The role of cancer cell-released extracellular vesicles: have we become closer to cancer pain treatment? *Extracell Vesicles Circ Nucleic Acids* 2024;5:785-7. <https://dx.doi.org/10.20517/evcna.2024.89>

Received: 12 Nov 2024 **First Decision:** 11 Dec 2024 **Revised:** 14 Dec 2024 **Accepted:** 18 Dec 2024 **Published:** 26 Dec 2024

Academic Editor: Yoke Peng Loh **Copy Editor:** Ting-Ting Hu **Production Editor:** Ting-Ting Hu

Abstract

The effective management of cancer pain continues to be a challenge because of our limited understanding of cancer pain mechanisms and, in particular, how cancer cells interact with neurons to produce pain. In a study published in *Pain*, Inyang *et al.* used a mouse model of human papillomavirus (HPV1)-induced oropharyngeal squamous cell carcinoma to show a role for cancer cell-derived extracellular vesicles (cancer sEVs) in cancer pain. They found that inhibiting the release of sEVs reduced spontaneous and evoked pain behaviors, and that pain produced by sEVs is due to activation of TRPV1 channels. An innovative approach was the use of publicly available human RNA-sequencing data from unstimulated cultured human dorsal root ganglia (DRG) that were exposed to human head and neck squamous cell carcinoma (HNSCC)-derived sEVs to identify signaling pathways involved in the nascent translation associated with nociception. These studies further our understanding of functional interactions between cancer cells and neurons, and suggest an approach to identify novel targets for the treatment of cancer pain.

Keywords: Extracellular vesicles, cancer pain, hyperalgesia, TRPV1, head and neck cancer, mouse



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.



MAIN TEXT

It is now well known that small extracellular vesicles released from cancer cells (cancer sEVs; size 30-150 nm) carry a wide array of biomolecules, including lipids, proteins, and nucleic acids, that promote tumor cell proliferation, invasion, and metastasis^[1], as well as axonogenesis^[2]. Only recently has the role of cancer sEVs in cancer pain been established^[3-5]. In their manuscript, Inyang *et al.* masterfully expanded on previously published evidence that cancer sEVs contribute to cancer pain, in particular, pain associated with head and neck squamous cell carcinoma (HNSCC)^[6].

Cancer pain is complex and, in addition to nociceptive and neuropathic components, involves unique oncogenic factors. sEVs secreted by cancer cells are one such factor that, by increasing the sensitivity of surrounding nociceptors, leads to pain and hypersensitivity^[5,7]. Considering that patients with HNSCC usually complain of spontaneous ongoing pain, as well as evoked pain hypersensitivity^[8,9], it is crucial that Inyang *et al.* measured both types of pain to prove the pronociceptive effect of cancer sEVs using a murine model of human papillomavirus (HPV1)-induced oropharyngeal squamous cell carcinoma. This increases the translational potential and clinical relevance of the study^[6].

Using various complementary approaches, the authors identified and thoroughly tested signaling pathways and clinically relevant targets for cancer sEVs *in vivo*. First, Inyang *et al.* clearly demonstrated that the pronociceptive effect of cancer sEVs is determined by their release from cancer cells^[6]. Second, the authors showed that cancer sEVs are quickly captured by sensory neurons, inducing the expression of ATF3, a marker of neuron damage. Importantly, they showed that administration of a sEV release inhibitor or implantation of cancer cells that release a limited amount of sEVs (meERL Rab27a^{+/-} and Rab27b^{-/-} cells) attenuated the development of pain, thus providing convincing evidence for a significant role of cancer sEVs in pain.

Another important and clinically relevant finding of this work is that cancer sEVs produce pain exclusively through open TRPV1 channels, and the role of these channels in the sensitization of primary nociceptors and, consequently, in the occurrence of pain was previously demonstrated in a bone cancer pain model^[7]. This was elegantly confirmed with QX-314, a positively charged lidocaine derivative that inhibits only neurons with open TRPV1 channels. In addition, TRPV1^{-/-} mice did not exhibit pain behaviors in response to cancer sEVs administration, and the ablation of TRPV1-positive neurons with resiniferatoxin prevented the development of both evoked and spontaneous pain in a murine model of HNSCC. Overall, these findings highlight the important role of TRPV1 channels in cancer-related pain.

A special, unique, and innovative approach of the authors was the use of publicly available human RNA-sequencing data from unstimulated cultured human dorsal root ganglia (DRG), which were exposed to human HNSCC-derived sEVs to identify signaling pathways involved in the nascent translation associated with nociception. These data revealed that eukaryotic initiation factor (eIF) 2 and 4, mammalian target of rapamycin (mTOR), and p70S6 kinase participated in the nascent protein translation associated with nociception. Importantly, the same pathways also trigger the translation of the nascent protein induced by cancer sEVs in mouse DRG neurons *in vitro*. Moreover, these pathways are involved in producing evoked and spontaneous pain behaviors in a murine model of HNSCC. Thus, this extremely important finding has made it possible to identify new clinically relevant targets for managing cancer pain.

Finally, like any outstanding work, the manuscript of Inyang *et al.* opens up new horizons for future research in identifying cancer pain mechanisms and new treatment approaches^[6]. For example, it is important to identify the difference between sEVs associated with painful and painless cancers such as skin

cancer. Another perspective is related to the creation of cancer cell-targeted sEV release inhibitors. For example, is it possible that by blocking the release of EVs that also remove cellular waste and thereby maintain cell viability, cancer cells will self-destruct? This may be a useful and effective adjuvant to chemotherapy.

In summary, identifying pain mediators specific to cancer is an extremely difficult, but very important and necessary task for improving the management of cancer pain and reducing opioid use. Excellent work has been done in the present study, which has allowed us to take a step forward in understanding the mechanisms underlying cancer pain by shedding additional light on the role of cancer sEVs in the progression of evoked and spontaneous pain. Undoubtedly, this work brings us closer to our main goal of safe and effective targeted treatment of cancer pain and the reduction of opioid use.

DECLARATIONS

Authors' contributions

Designed and wrote the initial draft of the manuscript: Khasabova IA

Participated in helping to edit the final manuscript: Simone DA, Khasabov SG

Conceived and designed the graphic abstract: Khasabova IA, Simone DA

Availability of data and materials

Not applicable.

Financial support and sponsorship

None.

Conflicts of interest

All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Copyright

© The Author(s) 2024.

REFERENCES

1. Sanderson RD, Bandari SK, Vlodavsky I. Proteases and glycosidases on the surface of exosomes: newly discovered mechanisms for extracellular remodeling. *Matrix Biol* 2019;75-76:160-9. DOI PubMed PMC
2. Madeo M, Colbert PL, Vermeer DW, et al. Cancer exosomes induce tumor innervation. *Nat Commun* 2018;9:4284. DOI PubMed PMC
3. Bhattacharya A, Janal MN, Veeramachaneni R, et al. Oncogenes overexpressed in metastatic oral cancers from patients with pain: potential pain mediators released in exosomes. *Sci Rep* 2020;10:14724. DOI PubMed PMC
4. Dubeykovskaya ZA, Tu NH, Garcia PDR, Schmidt BL, Albertson DG. Oral cancer cells release vesicles that cause pain. *Adv Biol* 2022;6:e2200073. DOI PubMed PMC
5. Khasabova IA, Khasabov SG, Johns M, et al. Exosome-associated lysophosphatidic acid signaling contributes to cancer pain. *Pain* 2023;164:2684-95. DOI PubMed PMC
6. Inyang KE, Evans CM, Heussner M, et al. HPV+ head and neck cancer-derived small extracellular vesicles communicate with TRPV1+ neurons to mediate cancer pain. *Pain* 2024;165:608-20. DOI PubMed PMC
7. Khasabova IA, Stucky CL, Harding-Rose C, et al. Chemical interactions between fibrosarcoma cancer cells and sensory neurons contribute to cancer pain. *J Neurosci* 2007;27:10289-98. DOI PubMed PMC
8. Connelly ST, Schmidt BL. Evaluation of pain in patients with oral squamous cell carcinoma. *J Pain* 2004;5:505-10. DOI PubMed
9. Salvo E, Campana WM, Scheff NN, et al. Peripheral nerve injury and sensitization underlie pain associated with oral cancer perineural invasion. *Pain* 2020;161:2592-602. DOI PubMed PMC